Beyond Air Inc XAIR

$2.13 -0.03 (-1.16%)

Valuation

Market cap
2,068,000
Revenue TTM
$7,680,000
Net income TTM
$-33,250,000
PE ratio
0.00
Forward PE
—
Profit margin
-432.94%
Debt to equity
7.89

Trading

Volume
6,595
Avg volume
271,248
Day's range
$2.12 – $2.22
Shares out
958,000
Stochastic %K
14%
Beta
0.21
Analysts
Strong Sell
Price target
$10.00

Price

Company profile

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospi...

Show more

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Industry
Medical Devices
Sector
Healthcare
Phone
516 665 8200
Website
https://www.beyondair.net
Address
900 Stewart Avenue, Suite 301, Garden City, United States

Latest news

Stocktwits

MikeyYuen Oct 19, 3:23 PM
$MSGY $ELPW $XAIR $MODD [[
0 replies
VernCapital Oct 14, 3:55 PM
$XAIR sub $2 soon.
0 replies
DingleberryDandy Oct 13, 7:38 PM
$XAIR market cap is now less than quarterly revenue FWIW
0 replies
kimrong Oct 9, 11:44 AM
$XAIR up up
0 replies
kimrong Oct 8, 8:44 PM
$XAIR 🚨 THIS IS STARTING TO LOOK SERIOUS 🚨 Q3 revenue just hit a RECORD $2.3M — up 30% QoQ and 27% YoY. And here’s the BIG part: 🔥 2026 revenue guidance: $8M 🔥 2027 guidance: $16–18M 🔥 2nd-gen LungFit PH is STILL under FDA review 🔥 FDA approval could significantly expand the addressable market 🔥 LungFit adoption is already accelerating The company literally says it expects demand to increase significantly after FDA approval. This means the market may be looking at a company BEFORE the real inflection point. Record revenue + accelerating adoption + FDA catalyst + 2X+ projected revenue growth. If FDA approval hits and volume starts pouring in… XAIR could move MUCH faster than people expect. 🚀🔥 Not financial advice. High-risk small cap.
1 replies
Usually_Im_Right Oct 8, 8:14 PM
$XAIR shorts deserve squeeze
0 replies
kimrong Oct 8, 8:14 PM
$XAIR THIS COULD GET VERY INTERESTING Q3 revenue hit a RECORD $2.3M, up 30% QoQ / 27% YoY. 2027 revenue guidance remains $16–18M, more than DOUBLE 2026 guidance. And the biggest catalyst is still ahead — FDA approval for Gen-2 LungFit PH. An insider just bought ~$56K of shares. $10 PT is already on the table. If FDA approval hits + volume comes in, this could move FAST. 🔥
1 replies
Aburose Oct 8, 8:09 PM
$XAIR Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M Est
0 replies